Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 84, Issue 6, Pages 1289-1301
Publisher
Springer Science and Business Media LLC
Online
2019-10-16
DOI
10.1007/s00280-019-03960-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improving Carboplatin Dosing Based on Estimated GFR
- (2018) Jan H. Beumer et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic model
- (2018) Tomohisa Nakada et al. Drug Metabolism and Pharmacokinetics
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
- (2017) Markus Joerger et al. THERAPEUTIC DRUG MONITORING
- Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
- (2016) M. Joerger et al. ANNALS OF ONCOLOGY
- Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
- (2016) Suresh S. Ramalingam et al. CLINICAL CANCER RESEARCH
- In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib
- (2016) Alex McCormick et al. XENOBIOTICA
- Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
- (2015) M. R. Middleton et al. ANNALS OF ONCOLOGY
- A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
- (2015) Hidenori Mizugaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies
- (2014) Ahmed Hamed Salem et al. CLINICAL PHARMACOKINETICS
- Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
- (2013) Judith Michels et al. CELL CYCLE
- Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
- (2013) M. Salemi et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
- (2013) Julie K. Horton et al. Frontiers in Oncology
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- PARP-1 protein expression in glioblastoma multiforme
- (2012) A. Galia et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer
- (2012) Frederick Klauschen et al. HISTOPATHOLOGY
- Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function
- (2012) Polina German et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- PARP inhibitors: its role in treatment of cancer
- (2011) Alice Chen Chinese Journal of Cancer
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Liquid chromatography–mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase
- (2008) Robert A. Parise et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation